Journal of Cellular Biochemistry · 2018 · 28 citations · 24 references
MedicineCancer BiologyOncologyMolecular OncologyNeoplasiaTumor ProgressionBladder CancerCancer BiomarkersCancer Cell SignalingMicrorna-mediated RegulationSignal Transduction In CancerCancer Signaling PathwaysCell Cycle InhibitionLoss-of-function AnalysisLoss-of-function EffectsMicrorna Function In CancerMicrorna In CancerMicrorna Regulation In CancerTherapeutic Target Identification
Bladder cancer is a common malignancy and miR-99a-5p has been reported to be downregulated in bladder cancer, but its function and the underlying mechanism in bladder cancer development remains largely unclear. Here, we report that miR-99a-5p expression was decreased in bladder cancer compared with the adjacent normal tissues. Receiver operating characteristic curve revealed that miR-99a-5p expression signature had area under curve value of 0.7989 in differing bladder cancer from the adjacent normal tissues. Bladder cancer patients with low expression of miR-99a-5p had a poor survival rate. Gain-of-function and loss-of-function approaches demonstrated that miR-99a-5p inhibited bladder cell proliferation and cell cycle. Furthermore, we identified that mammalian target of rapamycin (mTOR) was a direct target of miR-99a-5p and mTOR restore could rescue the proliferative ability of bladder cancer cells. Moreover, miR-99a-5p/mTOR axis regulated S6K1 phosphorylation. These suggested that miR-99a-5p/mTOR axis might be a therapeutic target for bladder cancer.
24
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2018 · 17K citations · Full text
Mahul B. Amin, Frederick L. Greene, Stephen B. Edge et al. · CA A Cancer Journal for Clinicians · 2017 · 6.5K citations · Full text
Medicine, Cancer Biology, Oncology +17
Xue-Jia Lin, Yutian Chong, Chen Xie et al. · The Lancet Oncology · 2015 · 274 citations
Bo–Sheng Li, Yongliang Zhao, Gang Guo et al. · PLoS ONE · 2012 · 242 citations · Full text